Renalytix Share Discussion Threads

[mr roper] 08/2/2023 08:15

Either way. It enables the show to stay on the road. I reckon it'll be nearer 200p this time next month. Funding out of the way for a while which enables the focus on rollout and revenue to come to the fore..and fda, partnerships etc

[idomeneo] 08/2/2023 07:38

More incineration of PIs' capital: Placement at £0.90 per Ordinary Share (90 pence). That's a 25% haircut. If they're losing $57m - $12m (savings)=$45m, that's just enough for 6 months of keeping the directors employed.

[sirshagalot] 06/2/2023 15:13

lol maybe even the rim!

[mr roper] 06/2/2023 14:28

Next leg up on the bowl underway

[wan] 30/1/2023 06:34

I am sure most readers will have already seen the following article, where Nephrology Associates of Syracuse, P.C. confirm that they now use KidneyIntelX. Readers will also note that “KidneyIntelX uses a set of newer, novel blood and urine tests to give better predictive values of whether someone is at high risk for kidney failure progression that will ultimately lead to a need for dialysis.” Note the discrete mention of a novel urine test -

If that use/reference of novel is correct, could that novel urine test be from the partnership with the University of Michigan-

Partnership agreement with the University of Michigan

NEW YORK, June 30, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), today announced a partnership with the University of Michigan ("UM") to extend the application of the KidneyIntelX:tm: platform to an expanded population of patients with established Chronic Kidney Disease (CKD) or at risk of developing CKD. RenalytixAI also announces a data sharing agreement with a top ten global pharmaceutical company.

RenalytixAI has entered into a partnership with the University of Michigan ("UM") under which RenalytixAI will be given access to the Clinical Phenotyping Resource and Biobank Core ("C-PROBE") of the UM George M. O'Brien Kidney Translational Core Center comprising of over 800 patients with a broad etiology of CKD with up to 10 years of follow up. Additionally, through this partnership, RenalytixAI has obtained an exclusive option under which it can license certain intellectual property surrounding the biomarker urinary Epithelial Growth Factor ("uEGF"). Prof. Matthias Kretzler and his team at UM have shown uEGF to be highly predictive of incident and progressive CKD1.

[wan] 28/1/2023 16:16

Sorry, but I have to disagree. As I said, I fully appreciate the importance of revenue growth, but for that we need a continuation of increasing coverage/adoption by Commercial Health Plans and PPO Networks, increased adoption/use by clinicians, Medicare coverage determination, and FDA approval.

The VA on its own will likely see a notable increase in the testing run rate, but that seems as though it will be incremental due to the implementation being on a phased basis over an approximate 18-month period, but nonetheless material over time.

A catalyst for a steep increase in the testing run rate would be partnering with a large diagnostic player, Dialysis player (Davita?), and/or large pharma. In my view it is likely that two or all of those will occur due to KindneyIntelX having a meaningful impact on a market that is too large for those entities to ignore! Such partnering would also negate not only funding requirements, but also the salesforce requirement.

As an additional attraction, I also see Renalytix expertise in AI & ML development and integration (beyond kidney disease), being of interest to those potential partners too.

[mr roper] 28/1/2023 12:21

If we go back 9mths the CEO was talking about run rates of 300 test a month per installation. That's what I'm looking to start showing up in the coming quarters, before increasing.The bigger carrot being the VA which we are now on the way to embedding in their own tech infrastructure. This opens the door to near 1m patients. I suspect we'll need a bigger salesforce for that and will raise or partner to drive it.

The more the outside world sees revenue growing with the massive carrot of the VA still to come then I suspect the climb back up for the share price could be just as explosive as the last 12 mths descent.

[hpcg] 28/1/2023 11:26

Nope - it is all about revenue. That is adoption, they are one and the same.

[faz] 28/1/2023 08:58

I do mot say they are simple mathematical formulae and sorcerors are not creators of modelling tools. Whatever, i hope renx do save lives.and thrive but they need to get thru this year successfully or i doubt they have a future

[substituted_pinions] 28/1/2023 03:10

[As a Yank, I've had to use Google Translate to bring my response to the King's English]

Blimey, faz... don't be daft. As a practitioner of the field, I don't appreciate your jiggery-pokery one bit. ML model responses aren't readily replaced by a simple mathematical formula and even if they were, by the time your ye olde 'excel masters' open up this minging application in an attempt to demonstrate this, they'd get laughed out of the primary school for being trollied.

Pip pip

[1jat] 27/1/2023 22:50

And what that means for the cash burn and how much new funding is needed to get to profitability.

[mr roper] 27/1/2023 08:03

Only thing that matters here is revenue growth and that will be the focus this year.

[faz] 26/1/2023 18:51

Wan, you'll see I wrote AI remains a conundrum, and if it was so blindingly obvious that the algorithms created by RENX are so far superior to relevant human endeavour then approval would have been granted a long time ago. A mathamatical formula is a subset of an algorithm, and if you;ve ever worked with excel professionals you'd never have dismissed their capability so blindly. 'Exclusive validated novel biomarkers' - get behind those words. It starts with mathamatical formulae, then into algorithsm that in theory generate outcomes that are then subject to differents sets of algorithmic calculations. People can do that too; hence the issue. it's a do or die year for RENX.

[wan] 26/1/2023 14:26

Given Renalytix intend to expand the indicated uses to include broader chronic kidney disease, health equity strategies and value based care, the following makes for an interesting read -

After another insightful conference this year, these are some of the key legal deal trends to expect from the health care and life sciences industries in 2023.
By THOMAS ROSE AND HEATHER MOREHOUSE ETTINGER

Jan 25, 2023

Focus on health equity and value-based care

If there is one thing the pandemic has brought to the top of everyone’s mind, it’s how disparities in access to care and other social determinants of health can impact patient outcomes and health care costs. The market is also shifting to value-based models, with organizations moving toward a holistic, integrated approach to patient care. Investors are seeing the benefits of pursuing health equity and quality, which can ultimately reduce costs, mitigate risk, and improve patient outcomes.

Life sciences companies are also shifting to a diversity mindset for R&D. For example, recent developments in mental health treatments, such as those targeting post-pardum depression and schizophrenia, are filling gaps in care for previously marginalized groups.

Going into 2023, M&A may begin to shift to those organizations championing quality and equity strategies that align with investor objectives. Strategic collaborations may be another viable option for organizations pursuing innovative new models and care integration. Health sciences companies and acquirers will also need to consider how value-based care models might impact financial risk and marketability of a product or service as they evaluate deal potential. Full article -

[wan] 26/1/2023 10:09

Staying with the pharma aspect and as referenced in todays news "The PRIME-CKD program builds on breakthrough findings in the Innovative Medicine Initiative 2 program BEAt-DKD (hxxps://www.beat-dkd.eu/ )"

Participants - Sanofi, Astellas, Eli Lilly, Bayer Pharma, Boehringer Ingelheim (scroll to bottom) -
And which has probably been extended as there are 7 EFPIA Partners -
(EFPIA corporate members -

[wan] 26/1/2023 09:44

One assumes that the pandemic set things back somewhat, but it's also worth recalling the original agreement between Renalytix and the University of Michigan, which adds weight to my pharma comments given the reference to a top 10 pharma -

NEW YORK, June 30, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced a partnership with the University of Michigan ("UM") to extend the application of the KidneyIntelX™ platform to an expanded population of patients with established Chronic Kidney Disease (CKD) or at risk of developing CKD. RenalytixAI also announces a data sharing agreement with a top ten global pharmaceutical company.

Partnership agreement with the University of Michigan
RenalytixAI has entered into a partnership with the University of Michigan ("UM") under which RenalytixAI will be given access to the Clinical Phenotyping Resource and Biobank Core ("C-PROBE") of the UM George M. O'Brien Kidney Translational Core Center comprising of over 800 patients with a broad etiology of CKD with up to 10 years of follow up. Additionally, through this partnership, RenalytixAI has obtained an exclusive option under which it can license certain intellectual property surrounding the biomarker urinary Epithelial Growth Factor ("uEGF"). Prof. Matthias Kretzler and his team at UM have shown uEGF to be highly predictive of incident and progressive CKD1.

The first phase of the partnership with UM, expected to be completed in 2020, will study the potential role of uEGF in further enhancing the prognostic performance of the KidneyIntelX platform in identifying patients at highest risk of fast-progressing Diabetic Kidney Disease ("DKD") and kidney failure. Significantly, through this partnership, RenalytixAI plans to advance the development and validation of the KidneyIntelX platform for expanded use in a broad CKD population.

The C-PROBE biobank provides RenalytixAI with access to a large repository of longitudinally followed CKD patients with matched urine and plasma samples coupled with extensive medical records. The patient population in the CPROBE study includes a range of CKD subtypes including those related to Diabetes, Hypertension and Glomerular Disease which combined, account for over 75 percent2 of all cases worldwide.

Data sharing agreement with a leading top ten global pharmaceutical company
RenalytixAI also announces that it has entered into a data sharing agreement with a top ten global pharmaceutical company providing RenalytixAI with access to a deep data repository from completed clinical studies in DKD. RenalytixAI plans to analyze this data in combination with corresponding biomarker data to evaluate KidneyIntelX performance in predicting patients' responses to novel therapeutic agents indicated to slow or prevent kidney function decline. Data analysis will also include evaluation of KidneyIntelX over multiple time points within a six year follow-up period, potentially demonstrating the value of dynamic, repeated KidneyIntelX measurements.

"The primary aim of our research has always been the translation of findings to clinical practice in order to improve patient care and kidney health," said Prof. Matthias Kretzler, Warner-Lambert/Parke-Davis Professor of Medicine, Nephrology/Internal Medicine, and Computational Medicine and Bioinformatics, University of Michigan Medical School. "The C-PROBE cohort was established with the express aim of enabling this translation to take place. We are very excited to partner with RenalytixAI in this endeavor and firmly believe that KidneyIntelX platform is an ideal vehicle to integrate the results of our work on uEGF with other biomarkers, bioinformatics and clinical research, with the goal of providing new, powerful solutions in managing CKD."

"These partnerships are both significant developments for our technology development roadmap and strategic objectives for the company," said Fergus Fleming, Chief Technology Officer and Co-founder of RenalytixAI. "Access to these data sets and samples potentially demonstrates the value of the KidneyIntelX platform and our ability to collaborate with leaders in discovery, clinical care and novel therapeutic development for kidney disease. We expect that gaining access to this clinical trial data, biomarker technology and the C-PROBE cohort will be key milestones in the development of expanded indications for KidneyIntelX, potentially allowing us to offer solutions to a greater number of the approximately 37 million patients currently estimated to have CKD."

KidneyIntelX is a first-in-class in vitro diagnostics platform that employs a proprietary artificial intelligence-enabled algorithm to combine diverse data inputs including validated blood-based biomarkers, a patient's genetics and extensive personalized patient data from EHR systems to generate a unique patient risk score. The current intended use for the test targets patients with CKD and type 2 diabetes which accounts for 20-30 percent of the estimated 37M US patients with CKD3.

[hpcg] 26/1/2023 09:17

I bought back in yesterday, there appears to be some significant strength behind the move.

[wan] 26/1/2023 08:36

Faz...you don't get exclusive, validated novel biomarkers on spread sheets. And if it was as simple as a dressed-up spread sheet, the FDA would probably have already made its decision!

Readers will already appreciate that FDA approval is not required, as demonstrated by the ever-growing Commercial Health Plans and PPO Networks and the VA supporting KidneyIntelX, and indeed as exemplified by todays announced partnership. However, in my view, FDA approval is likely to provide a catalyst to diagnostic and pharma partnerships (and no doubt speed adoption rates), but given the level of supporting information delivered to the FDA, and indeed the validation provided by todays news, I would also not completely discount something ahead of the FDA decision.

[faz] 26/1/2023 08:12

I thnk its more likkely RENX is clamouring for cash and if this chucks in anything then all to the good. FDA blessing is a must. I now hold a trading position at around 100p so well up, but this year is do or die for the company. AI remains a conundrum - just a dressed-up excel spreadsheet or something more than the best statisticians do routinely for the GSK, AZ etc?

[wan] 26/1/2023 08:02

Todays news is a very strong validation of the technology and indeed the potential of the platform beyond prognosis.

Food for thought: With Renalytix clearly playing a pivotal role in the consortium, with exclusive access to a range of yet to be confirmed novel biomarkers, and given that the consortiums aim is to validate and implement in clinical practice, novel biomarker-based tests that predict response to existing drugs used by patients with chronic kidney disease, it may well make Renalytix an even more attractive diagnostic and pharma partner (potentially removing the need or reducing the level of any future fundraise).

[mr roper] 26/1/2023 07:36

Excellent news. Certainly looks to be a fair amount going on. I'm not seeing any obstacles to a fundraise at a significantly higher price (if its required obviously as any type of partnership may negate the need)

[faz] 26/1/2023 07:09

RNS out - maybe why the US market was excited yesterday

[mr roper] 25/1/2023 21:07

hxxps://www.centralnewyorkmdnews.com/articles/nephrology-associates-of-syracuse-p-c-give-patients-a-comprehensive-united-approach-to-kidney-care/

Until recently, clinicians who attempted to predict kidney function decline couldn’t be 100% certain. Nephrology Associates of Syracuse, P.C. now uses KidneyIntelX™, which provides sophisticated and precise data to help forecast rapid decline among their CKD patients. Primarily limited for use on patients with diabetes and those who are nephrotic, KidneyIntelX scores patients based on their risk of experiencing rapid kidney failure progression.

“Although we can use charts and graphs to look at the rate at which a patient’s creatinine is rising, you’re only estimating what [that future level] is going to be,” Dr. Chaffin says. “KidneyIntelX uses a set of newer, novel blood and urine tests to give better predictive values of whether someone is at high risk for kidney failure progression that will ultimately lead to a need for dialysis

[mr roper] 25/1/2023 16:55

It'll be nearer $5 soon enough. Once the big mo takes hold the Yanks will eat it up. Heck of a bowl on the chart